share_log

LIXTE Biotechnology Provides Update On Recent Activities And Developments; Collaboration With NKI And Funding Support For New Colorectal Cancer Clinical Trial By Major Pharma Co; Preclinical Data Published In Journal EMBO Reports Shows LB-100 As...

Benzinga ·  Aug 19 08:42

LIXTE Biotechnology Provides Update On Recent Activities And Developments; Collaboration With NKI And Funding Support For New Colorectal Cancer Clinical Trial By Major Pharma Co; Preclinical Data Published In Journal EMBO Reports Shows LB-100 As Potentially Enhancing The Benefit Of Immunotherapy

-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company-

-Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer-

-Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy-

-LIXTE to Present at Two Upcoming Investor Conferences-

PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's recent activities.

"We are encouraged by the growing interest shown by major pharmaceutical companies in our proprietary compound, LB-100, as demonstrated by their support in clinical trial collaborations," said Bas van der Baan, LIXTE's President and Chief Executive Officer.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment